Disease Info Card

Inflammatory Myofibroblastic Tumor

Information about Inflammatory Myofibroblastic Tumor: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Inflammatory Myofibroblastic Tumor

Most recent studies have shown that Inflammatory Myofibroblastic Tumor shares some biological mechanisms with carcinoma, fibroma, fibrosis, granuloma, granuloma-plasma-cell, inflammation, liver-diseases, liver-inflammatory-myofibroblastic-tumor, liver-neoplasms, lung-neoplasms, lymphoma, malignant-neoplasms, malignant-paraganglionic-neoplasm, neoplasm-metastasis, neoplasms, neoplasms-muscle-tissue, pain, plasma-cell-granuloma-pulmonary, pseudotumor, sarcoma.

Among the many pathways, these few ones have gauged particular interests from scientists studying Inflammatory Myofibroblastic Tumor, and have been seen in publications frequently: Cell Cycle, Cell Differentiation, Cell Growth, Cell Proliferation, Coagulation, Cytokine Production, Drug Resistance, Enucleation, Granuloma Formation, Immune Response, Inflammatory Response, Localization, Metaphase, Mitosis, Oncogenesis, Ossification, Pathogenesis, Plasma Cell Differentiation, Regeneration

Quite a number of genes have been found to play important roles in Inflammatory Myofibroblastic Tumor, such as ACVRL1, ALK, CD34, CD68, CR1, CR2, CRP, CTLA4, DES, HLA-DQA1, KIT, NOD2, S100A1, S100B, TP53, TRIT1, VIM. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.